Association of maternal pancreatic function and foetal growth in rats treated with DFU, a selective cyclooxygenase-2 inhibitor

• Autorzy: Burdan F , Szumilo J. , Dudka J. , Szumilo M. , Korobowicz A. , Chatterjee S. , Klepacz R.
• Języki publikacji: EN

Abstrakty

EN

Constitutive (COX-1) and inducible (COX-2) cyclooxygenase isoforms have been detected in various mammalian tissues. Their activity is blocked by non-steroidal anti-inflammatory drugs that may induce various side reactions. The aim of the study was to evaluate the effects of DFU, a selective COX-2 inhibitor, on exocrine and endocrine pancreatic function and the immunoexpression of both COX isoforms in maternal and foetal rat pancreases. The compound was administered to pregnant Wistar rats once daily from the 8th to the 21st day of gestation. Glucose level and amylase activity were determined in the maternal sera. Maternal and foetal pancreases were examined histologically. Immunoexpression of COX-1 and COX-2 was also evaluated. Both biochemical parameters, as well as the histological structure of the pancreas were undisturbed in the dams and their foetuses. The maternal glucose level was found to be an important factor for foetal growth. Strong cytoplasmic COX-1 immunostaining was observed in acinar secretory cells, whereas in islets the immune reaction was weak. Endocrine cells also revealed strong cytoplasmic COX-2 staining in the maternal and foetal pancreases. Acinar cells exhibited nuclear reaction, which was strong in the foetal but weak in the maternal pancreases. No differences in COX immunoexpression were found between the DFU-exposed and the control groups in either mothers or foetuses. It should be stressed that DFU administered throughout mid and late pregnancy in rats did not change maternal or foetal pancreatic morphology or immunoexpression of either of the main COX isoforms in the organ.

Słowa kluczowe

EN

pregnancy; glucose; mammal; reaction; diabetes; fetal growth; morphology; pancreatic function; rat; cyclooxygenase isoform; antiinflammatory drug; late pregnancy; macrosomia; immunoexpression; anatomy; fetus; tissue

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2007
• Tom: 66
• Numer: 3
• Opis fizyczny: p.172-180,fig.,ref.

Twórcy

autor

Burdan F

• Medical University of Lublin, Jaczewskiego 4, 20-090 Lublin, Poland

autor

Szumilo J.

autor

Dudka J.

autor

Szumilo M.

autor

Korobowicz A.

autor

Chatterjee S.

autor

Klepacz R.

Bibliografia

• 1. Alhan E, Kalyoncu NI, Ercin C, Kural BV (2004) Effects of the celecoxib on the acute necrotizing pancreatitis in rats. Inflammation, 28: 303–309.
• 2. Alm P, Ekstrom P, Henningsson R, Lundquist I (1999) Morphological evidence for the existence of nitric oxide and carbon monoxide pathways in the rat islets of Langerhans: an immunocytochemical and confocal microscopical study. Diabetologia, 42: 978–986.
• 3. Burdan F, Chalas A, Szumilo J (2006) Cyclooxygenase and prostanoids — biological implications. Post Hig Med Dosw, 60: 129–141.
• 4. Burdan F, Radzikowska E, Wyskiel M, Urbanowicz Z (1999) Drug-induced pancreatic injury during pregnancy. In: Mackiewicz Z (ed) Selected surgical problems. Vol. 4. Fundacja Polski Przegląd Chirurgiczny, Warszawa, pp. 168–171.
• 5. Burdan F, Szumilo J, Dudka J, Korobowicz A, Fronczek A, Klepacz R, Wojtowicz Z (2007) Pancreatic morphology in pregnant rats exposed to DuP-697 — the irreversible, highly selective cyclooxygenase-2 inhibitor. Ann Univ Mariae Curie Sklodowska Med, 62 (in press).
• 6. Burdan F, Szumilo J, Dudka J, Radzikowska E, Klepacz R (2006) Constitutive and inducible cyclooxygenase isoforms expressed in rat pancreas. Ann Univ Mariae Curie Sklodowska Med, 61: 572–575.
• 7. Burdan F, Szumilo J, Klepacz R, Dudka J, Korobowicz A, Tokarska E, Cendrowska-Pinkosz M, Madej B, Klepacz L (2004) Gastrointestinal and hepatic toxicity of selective and non-selective cyclooxygenase-2 inhibitors in pregnant and non-pregnant rats. Pharmacol Res, 50: 533–543.
• 8. Burdan F (2005) Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats — DFU and piroxicam study. Toxicology, 211: 12–25.
• 9. Carrillo-Jimenez R, Nurnberger M (2000) Celecoxib-induced acute pancreatitis and hepatitis: a case report. Arch Intern Med, 160: 553–554.
• 10. de Almeida JL, Jukemura J, Coelho AM, Patzina RA, Machado MC, da Cunha JE (2006) Inhibition of cyclooxygenase-2 in experimental severe acute pancreatitis. Clinics, 61: 301–306.
• 11. Ethridge RT, Chung DH, Slogoff M, Ehlers RA, Hellmich MR, Rajaraman S, Saito H, Uchida T, Evers BM (2002) Cyclooxygenase-2 gene disruption attenuates the severity of acute pancreatitis and pancreatitis-associated lung injury. Gastroenterology, 123: 1311–1322.
• 12. Fitzpatrick FA (2004) Cyclooxygenase enzymes: regulation and function. Curr Pharm Des, 10: 577–588.
• 13. Fuglsang J, Lauszus FF, Fisker S, Flyvbjerg A, Ovesen P (2005) Growth hormone binding protein and maternal body mass index in relation to placental growth hormone and insulin requirements during pregnancy in type 1 diabetic women. Growth Horm IGF Res, 15: 223–230.
• 14. Gabbe SG, Quilligan EJ (1977) Fetal carbohydrate metabolism: its clinical importance. Am J Obstet Gynecol, 127: 92–103.
• 15. Han X, Chen S, Sun Y, Nadler JL, Bleich D (2002) Induction of cyclooxygenase-2 gene in pancreatic betacells by 12-lipoxygenase pathway product 12-hydroxyeicosatetraenoic acid. Mol Endocrinol, 16: 2145–2154.
• 16. Hedderson MM, Weiss NS, Sacks DA, Pettitt DJ, Selby JV, Quesenberry CP, Ferrara A (2006) Pregnancy weight gain and risk of neonatal complications: macrosomia, hypoglycemia, and hyperbilirubinemia. Obstet Gynecol, 108: 1153–161.
• 17. Hughes JH, Easom RA, Wolf BA, Turk J, McDaniel ML (1989) Interleukin 1-induced prostaglandin E2 accumulation by isolated pancreatic islets. Diabetes, 38: 1251–1257.
• 18. Ishizuka T, Klepcyk P, Liu S, Panko L, Liu S, Gibbs EM, Friedman JE (1999) Effects of overexpression of human GLUT4 gene on maternal diabetes and fetal growth in spontaneous gestational diabetic C57BLKS/J Lepr(db/+) mice. Diabetes, 48: 1061–1069.
• 19. Jansson T, Cetin I, Powell TL, Desoye G, Radaelli T, Ericsson A, Sibley CP (2006) Placental transport and metabolism in fetal overgrowth — a workshop report. Placenta, 27 (Suppl. A): S109–S113.
• 20. Kautzky-Willer A, Bancher-Todesca D (2003) Gestational diabetes. Wien Med Wochenschr, 153: 478–484.
• 21. Koliopanos A, Friess H, Kleeff J, Roggo A, Zimmermann A, Buchler MW (2001) Cyclooxygenase 2 expression in chronic pancreatitis: correlation with stage of the disease and diabetes mellitus. Digestion, 64: 240–247.
• 22. Lucas MJ (2001) Diabetes complicating pregnancy. Obstet Gynecol Clin North Am, 28: 513–536.
• 23. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest, 110: 851–860.
• 24. Miedzybrodzki R (2004) Trends in nonsteroidal antiinflammatory drug development and application. Post Hig Med Dosw, 58: 438–448.
• 25. Neufeld ND, Corbo L (1982) Increased fetal insulin receptors and changes in membrane fluidity and lipid composition. Am J Physiol, 243: E246–E250.
• 26. Shanmugam N, Todorov IT, Nair I, Omori K, Reddy MA, Natarajan R (2006) Increased expression of cyclooxygenase-2 in human pancreatic islets treated with high glucose or ligands of the advanced glycation endproduct-specific receptor (AGER), and in islets from diabetic mice. Diabetologia, 49: 100–107.
• 27. Sjoholm A (1991) Inhibition of fetal rat pancreatic betacell replication by interleukin-1 beta in vitro is not mediated through pertussis toxin-sensitive G-proteins, a decrease in cyclic AMP, or protease activation. FEBS Lett, 289: 249–252.
• 28. Streck RD, Kumpf SW, Ozolins TR, Stedman DB (2003) Rat embryos express transcripts for cyclooxygenase-1 and carbonic anhydrase-4, but not for cyclooxygenase-2 during organogenesis. Birth Defects Res B Dev Reprod Toxicol, 68: 57–69.
• 29. Tabatabaie T, Waldon AM, Jacob JM, Floyd RA, Kotake Y (2000) COX-2 inhibition prevents insulin-dependent diabetes in low-dose streptozotocin-treated mice. Biochem Biophys Res Commun, 273: 699–704.
• 30. Tran PO, Gleason CE, Poitout V, Robertson RP (1999) Prostaglandin E(2) mediates inhibition of insulin secretion by interleukin-1 beta. J Biol Chem, 274: 31245–3128.
• 31. Warner TD, Mitchell JA (2004) Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J, 18: 790–804.
• 32. Zabel-Langhennig A, Holler B, Engeland K, Mossner J (1999) Cyclooxygenase-2 transcription is stimulated and amylase secretion is inhibited in pancreatic acinar cells after induction of acute pancreatitis. Biochem Biophys Res Commun, 265: 545–549.